ログイン

CLINICAL CHEMISTRY

CLINICAL CHEMISTRY
32問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    Which of the following approaches to analyzer automation can use mixing paddles to stir? a. Discrete analysis b. Centrifugal analysis c. Continuous flow d. Dry chemistry slide analysis

    a. Discrete analysis

  • 2

    Which of the following types of analyzers offers random access capabilities? a. Discrete analyzers b. Continuous flow analyzers c. Centrifugal analyzers d. None of these

    a. Discrete analysis

  • 3

    All of the following are primary considerations in the selection of an automated chemistry analyzers, except: a. How reagents are added or mixed b. The cost of consumables c. Total instrument cost d. The labor component

    a. How reagents are added or mixed

  • 4

    Dwell time refers to: a. Time between initiation of a test and the completion of analysis b. Number of tests an instrument can handle in a specified time c. Ability of an instrument to perform a defined workload in a specified time. d. None of these

    a. Time between initiation of a test and the completion of analysis

  • 5

    All of the following are advantages to automation, EXCEPT: a. Correction for deficiencies inherent in methodologies b. Increased number of tests performed c. Minimized labor component d. Use of small amounts of samples and reagents in comparison to manual procedures.

    a. Correction for deficiencies inherent in methodologies

  • 6

    Which of the following steps in automation generally remains a manual process in most laboratories? a. Preparation of the sample b. Specimen measurement and delivery c. Reagent delivery d. Chemical reaction phase

    a. Preparation of the sample

  • 7

    Which of the following chemistry analyzers uses slides to contain the entire reagent system? a. VITROS analyzers b. ACA analyzers c. Synchron analyzers d. None of these

    a. VITROS analyzers

  • 8

    Modifications in microsampling and reagent dispensing improve which of the following phases in clinical testing? a. Physician ordering phase b. Preanalytical phase c. Analytical phase d. Postanalytical phase e. All of the above phases

    c. Analytical phase

  • 9

    Bidirectional communication between the chemistry analyzer and the laboratory information system has had the greatest impact on which of the following phases of clinical testing? a. Preanalytical b. Analytical c. Postanalytical d. All of the above e. None of the above

    c. Postanalytical

  • 10

    Mass spectrometry identifies analytes based on: a. Mass-to-charge ratio b. Retention factor c. Density of the band d. Molecular weight e. Solubility in the mobile phase

    a. Mass-to-charge ratio

  • 11

    Which of the following light sources is used in atomic absorption spectrophotometry? a. Hollow-cathode lamp b. Xenon arc lamp c. Tungsten light d. Deuterium lamp e. Laser

    a. Hollow-cathode lamp

  • 12

    Which of the following techniques has the highest potential sensitivity? a. Chemiluminescence b. Fluorescence c. Turbidimetry d. Nephelometry e. Phosphorescence

    a. Chemiluminescence

  • 13

    Which electrochemical assay measures current at fixed potential? a. Amperometry b. Anodic stripping voltammetry c. Coulometry d. Analysis with ISEs e. Electrophoresis

    a. Amperometry

  • 14

    Which of the following is the most sensitive detector for spectrophotometry? a. Photomultiplier b. Phototube c. Electron multiplier d. Photodiode array e. All are equally sensitive

    a. Photomultiplier

  • 15

    It is reported that the greatest percentage of laboratory errors occur during the ______ phase. a. Preanalytical b. Analytical c. Postanalytical d. Proficiency e. Phlebotom

    a. Preanalytical

  • 16

    Interference studies typically use _____ as an interferent. a. All of these b. Hemolyzed red cells c. Highly icteric samples d. Highly lipemic samples

    a. All of these

  • 17

    A reference range can be verified by: a. Testing as few as 20 normal donor specimens b. Literature and vendor material review c. Using samples from previously tested hospital patients d. using pharmacy-provided Plasmanate spiked with target concentrations

    a. Testing as few as 20 normal donor specimens

  • 18

    Reference interval transference studies: a. Are used to verify a reference interval b. Are used to establish a reference interval c. Require as many as 120 donors d. Use a 68% reference limit for acceptability.

    a. Are used to verify a reference interval

  • 19

    If two methods agree perfectly in a method comparison study, the slope equals ______ and the y-intercept equals ______. a. 1.0, 0.0 b. 0.0, 1.0 c. 1.0,1.0 d. 0.0, 0.0 e. 0.5, 0.5

    a. 1.0, 0.0

  • 20

    What are the major contributing factors to repetitive strain injuries? a. Position/posture, applied force, and frequency of repetition. b. Inattention on the part of the laboratorian c. Temperature and vibration d. Fatigue, clumsiness, and lack of coordination

    a. Position/posture, applied force, and frequency of repetition

  • 21

    Which of the following is the proper means of disposal for the type of waste? a. Microbiologic waste by steam sterilization b. Xylene into the sewer system c. Mercury by burial d. Radioactive waste by incineration

    a. Microbiologic waste by steam sterilization

  • 22

    One liter of 4N sodium hydroxide (strong base) in a glass 1L beaker accidentally fell and spilled on the laboratory floor. The first step is to: a. Call 911 b. Alert and evacuate those in the immediate area out of harm’s way. c. Throw some kitty litter on the spill d. Squirt water on the spill to dilute the chemical. e. Neutralize with absorbing materials in a nearby spill kit

    b. Alert and evacuate those in the immediate area out of harm’s way.

  • 23

    A fire caused by a flammable liquid should be extinguished using which type of extinguisher? a. Class B b. Halogen c. Pressurized water d. Class C

    a. Class B

  • 24

    A patient’ serum sample was placed on the chemistry analyzer and the output indicated “out of range” for the measurement of creatine kinase (CK) enzyme. A dilution of the patient serum was required. Which of the following should be used to prepare a dilution patient serum? a. Deionized water b. Tap water c. Another patient’s serum with confirmed, low levels of CK d. Type III water e. Type I water

    e. Type I water

  • 25

    What is the molarity for a solution containing 100 g of NaCl made up to 500 mL with distilled water? Assume a GMW of approx. 58 grams. a. 3.45 M b. 1.72 M c. 290 M d. 5.27 M

    a. 3.45 M

  • 26

    What is the percent (w/v) for a solution containing 100 g of NaCl made up to 500 mL with distilled water? a. 20% b. 5% c. 29% d. 58%

    a. 20%

  • 27

    What is the value in mg/dL for a solution containing 10 mg of CaCl2 made with 100 mL of distilled water? a. 10 b. 100 c. 50 d. Cannot be determined without additional information

    a. 10

  • 28

    REFERENCE METHODS ELECTROLYTES -

    AAS

  • 29

    REFERENCE METHODS HBA1C

    -HPLC

  • 30

    REFERENCE METHODS LIPASE-

    CHERRY AND CRANDALL METHOD

  • 31

    REFERENCE METHODS AMS-

    SACCHAROGENIC METHOD

  • 32

    REFERENCE METHODS ALP-

    BOWERS AND MCCOMB METHOD

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    Which of the following approaches to analyzer automation can use mixing paddles to stir? a. Discrete analysis b. Centrifugal analysis c. Continuous flow d. Dry chemistry slide analysis

    a. Discrete analysis

  • 2

    Which of the following types of analyzers offers random access capabilities? a. Discrete analyzers b. Continuous flow analyzers c. Centrifugal analyzers d. None of these

    a. Discrete analysis

  • 3

    All of the following are primary considerations in the selection of an automated chemistry analyzers, except: a. How reagents are added or mixed b. The cost of consumables c. Total instrument cost d. The labor component

    a. How reagents are added or mixed

  • 4

    Dwell time refers to: a. Time between initiation of a test and the completion of analysis b. Number of tests an instrument can handle in a specified time c. Ability of an instrument to perform a defined workload in a specified time. d. None of these

    a. Time between initiation of a test and the completion of analysis

  • 5

    All of the following are advantages to automation, EXCEPT: a. Correction for deficiencies inherent in methodologies b. Increased number of tests performed c. Minimized labor component d. Use of small amounts of samples and reagents in comparison to manual procedures.

    a. Correction for deficiencies inherent in methodologies

  • 6

    Which of the following steps in automation generally remains a manual process in most laboratories? a. Preparation of the sample b. Specimen measurement and delivery c. Reagent delivery d. Chemical reaction phase

    a. Preparation of the sample

  • 7

    Which of the following chemistry analyzers uses slides to contain the entire reagent system? a. VITROS analyzers b. ACA analyzers c. Synchron analyzers d. None of these

    a. VITROS analyzers

  • 8

    Modifications in microsampling and reagent dispensing improve which of the following phases in clinical testing? a. Physician ordering phase b. Preanalytical phase c. Analytical phase d. Postanalytical phase e. All of the above phases

    c. Analytical phase

  • 9

    Bidirectional communication between the chemistry analyzer and the laboratory information system has had the greatest impact on which of the following phases of clinical testing? a. Preanalytical b. Analytical c. Postanalytical d. All of the above e. None of the above

    c. Postanalytical

  • 10

    Mass spectrometry identifies analytes based on: a. Mass-to-charge ratio b. Retention factor c. Density of the band d. Molecular weight e. Solubility in the mobile phase

    a. Mass-to-charge ratio

  • 11

    Which of the following light sources is used in atomic absorption spectrophotometry? a. Hollow-cathode lamp b. Xenon arc lamp c. Tungsten light d. Deuterium lamp e. Laser

    a. Hollow-cathode lamp

  • 12

    Which of the following techniques has the highest potential sensitivity? a. Chemiluminescence b. Fluorescence c. Turbidimetry d. Nephelometry e. Phosphorescence

    a. Chemiluminescence

  • 13

    Which electrochemical assay measures current at fixed potential? a. Amperometry b. Anodic stripping voltammetry c. Coulometry d. Analysis with ISEs e. Electrophoresis

    a. Amperometry

  • 14

    Which of the following is the most sensitive detector for spectrophotometry? a. Photomultiplier b. Phototube c. Electron multiplier d. Photodiode array e. All are equally sensitive

    a. Photomultiplier

  • 15

    It is reported that the greatest percentage of laboratory errors occur during the ______ phase. a. Preanalytical b. Analytical c. Postanalytical d. Proficiency e. Phlebotom

    a. Preanalytical

  • 16

    Interference studies typically use _____ as an interferent. a. All of these b. Hemolyzed red cells c. Highly icteric samples d. Highly lipemic samples

    a. All of these

  • 17

    A reference range can be verified by: a. Testing as few as 20 normal donor specimens b. Literature and vendor material review c. Using samples from previously tested hospital patients d. using pharmacy-provided Plasmanate spiked with target concentrations

    a. Testing as few as 20 normal donor specimens

  • 18

    Reference interval transference studies: a. Are used to verify a reference interval b. Are used to establish a reference interval c. Require as many as 120 donors d. Use a 68% reference limit for acceptability.

    a. Are used to verify a reference interval

  • 19

    If two methods agree perfectly in a method comparison study, the slope equals ______ and the y-intercept equals ______. a. 1.0, 0.0 b. 0.0, 1.0 c. 1.0,1.0 d. 0.0, 0.0 e. 0.5, 0.5

    a. 1.0, 0.0

  • 20

    What are the major contributing factors to repetitive strain injuries? a. Position/posture, applied force, and frequency of repetition. b. Inattention on the part of the laboratorian c. Temperature and vibration d. Fatigue, clumsiness, and lack of coordination

    a. Position/posture, applied force, and frequency of repetition

  • 21

    Which of the following is the proper means of disposal for the type of waste? a. Microbiologic waste by steam sterilization b. Xylene into the sewer system c. Mercury by burial d. Radioactive waste by incineration

    a. Microbiologic waste by steam sterilization

  • 22

    One liter of 4N sodium hydroxide (strong base) in a glass 1L beaker accidentally fell and spilled on the laboratory floor. The first step is to: a. Call 911 b. Alert and evacuate those in the immediate area out of harm’s way. c. Throw some kitty litter on the spill d. Squirt water on the spill to dilute the chemical. e. Neutralize with absorbing materials in a nearby spill kit

    b. Alert and evacuate those in the immediate area out of harm’s way.

  • 23

    A fire caused by a flammable liquid should be extinguished using which type of extinguisher? a. Class B b. Halogen c. Pressurized water d. Class C

    a. Class B

  • 24

    A patient’ serum sample was placed on the chemistry analyzer and the output indicated “out of range” for the measurement of creatine kinase (CK) enzyme. A dilution of the patient serum was required. Which of the following should be used to prepare a dilution patient serum? a. Deionized water b. Tap water c. Another patient’s serum with confirmed, low levels of CK d. Type III water e. Type I water

    e. Type I water

  • 25

    What is the molarity for a solution containing 100 g of NaCl made up to 500 mL with distilled water? Assume a GMW of approx. 58 grams. a. 3.45 M b. 1.72 M c. 290 M d. 5.27 M

    a. 3.45 M

  • 26

    What is the percent (w/v) for a solution containing 100 g of NaCl made up to 500 mL with distilled water? a. 20% b. 5% c. 29% d. 58%

    a. 20%

  • 27

    What is the value in mg/dL for a solution containing 10 mg of CaCl2 made with 100 mL of distilled water? a. 10 b. 100 c. 50 d. Cannot be determined without additional information

    a. 10

  • 28

    REFERENCE METHODS ELECTROLYTES -

    AAS

  • 29

    REFERENCE METHODS HBA1C

    -HPLC

  • 30

    REFERENCE METHODS LIPASE-

    CHERRY AND CRANDALL METHOD

  • 31

    REFERENCE METHODS AMS-

    SACCHAROGENIC METHOD

  • 32

    REFERENCE METHODS ALP-

    BOWERS AND MCCOMB METHOD